Home > Gastroenterology > Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By
Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 3, KEYNOTE-394
Pembrolizumab plus best supportive care outperformed placebo plus best supportive care in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) in the second-line treatment of patients with advanced hepatocellular carcinoma (HCC). Moreover, a meta-analysis of the phase 3 KEYNOTE-394 and KEYNOTE-240 trials provided support for global generalisability of the results [1]. Pembrolizumab, a PD-1 inhibitor, added to best supportive care demonstrated superiority over placebo plus best supportive care in a phase 2 (KEYNOTE-224; NCT02702414) and a phase 3 (KEYNOTE-240; NCT02702401) trial [2,3]. The current, multicentre, phase 3 KEYNOTE-394 study (NCT03062358...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on